Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases (August 31, 2026 ) by Eli Lilly and Company Merida’s antibody-engineering platform is designed to enable precise, durable removal of disease-causing antibodies, while preserving normal immune function Initial Phase 1 data show MER511 achieved robust reductions in pathogenic thyroid-stimulating antibodies with a favorable initial safety profile

Colossal AI spinoff hits $3.8 billion valuation, targets aging with first model (August 20, 2026 ) by Sasha Richie Astromech just announced new funding to develop artificial intelligence that can predict biological outcomes. Astromech, an artificial intelligence venture gestated at Dallas’ resident sci-fi startup, secured $20 million in new funding at a $3.8 billion valuation, the company announced Thursday. Founded

Roche pens $2.5B pact for Hanmi’s clinical-stage obesity drug targeting less-explored mechanism (August 24, 2026 ) by James Waldron Roche has taken its obesity strategy into uncharted territory via a $190 million upfront payment for a clinical-stage UCN2 (urocortin-2) analog from South Korea’s Hanmi Pharm. UCN2 is a signaling protein that is elevated in people with chronic heart failure. The

Lilly buys AtaiBeckley for $2.8B upfront to challenge J&J for psychedelic mental health market (July 16, 2026 ) by Nick Paul Taylor Eli Lilly has struck a deal to buy AtaiBeckley for $2.8 billion upfront, continuing its takeover spree to move into a psychedelic mental health sector targeted by companies including Johnson & Johnson. AtaiBeckley’s lead candidate is BPL-003, a

Kalohexis is working on peptide therapies, including one for obesity that could offer an alternative approach to the GLP-1s that currently dominate the weight loss space. (July 8, 2026 ) by Tristan Manalac Kalohexis is working on peptide therapies, including one for obesity that could offer an alternative approach to the GLP-1s that currently dominate the weight loss space. Kalohexis,

Insilico Medicine And SK Biopharmaceuticals Achieved AI-powered Drug Discovery Collaboration Worth Up to 2.5 Billion for Neuroimmune Disorders (June 22, 2026) by Insilico Medicine CAMBRIDGE, Mass., June 22, 2026 /PRNewswire/ — Insilico Medicine (“Insilico”, 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and SK Biopharmaceuticals, a Korean-based company leads the way in biotech innovation with groundbreaking drug research,

Merck adds to biopharma’s AI agenda with up to $510M+ Protillion pact (June 17, 2026) by Tristan Manalac Merck will use Protillion Biosciences’ tech to design biologic therapies for therapies across undisclosed indications. The next stop on biopharma’s AI train is Merck, which is bringing on California’s Protillion Biosciences to combine large-scale data generation and AI design to advance a

Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform (June 8, 2026) by J&J Global Media Relations NEW BRUNSWICK, NJ (June 8, 2026) – Johnson & Johnson (NYSE: JNJ) today announced it has entered into a definitive agreement to acquire Firefly Bio, Inc., a biotechnology company advancing its proprietary Firelink™ degrader

Moderna and other groups get $60 million to develop Ebola vaccine (June 1, 2026) by By Jennifer Rigby, Mariam E Sunny and Julie Steenhuysen Isomorphic Labs, which hasn’t yet disclosed a molecule or reached the clinic, breaks the recent trend of investors putting their money behind more mature and de-risked assets. June 1 (Reuters) – Global health organisation CEPI will

AI-fueled Isomorphic bags $2.1B, the second largest biotech round ever (May 13, 2026) by Tristan Manalac Isomorphic Labs, which hasn’t yet disclosed a molecule or reached the clinic, breaks the recent trend of investors putting their money behind more mature and de-risked assets. Alphabet’s AI-forward biotech Isomorphic Labs has brought in $2.1 billion, clocking what analysts say is “the second